Unique Cytochrome P450 Activity and Inhibitor Screening Assays from BioVision!

MILPITAS, Calif. - Sept. 8, 2015 - PRLog -- BioVision proudly announces the launch of a unique line of Cytochrome P450 (CYP) activity and ligand screening kits which use specific fluorescent substrates and validated inhibitors for each CYP isoform. The detection chemistry offers low signal-to-noise ratio for kinetic measurements like never before. These kits come with active human P450 enzymes coexpressed with NADPH reductase in one single membrane system (Check out our EZCyp™ Active Human Cytochrome P450 product line link below). This positive control allows data validation and inhibitor rank-ordering with absolute confidence.

Key Features:

o Easy-to-use, highly sensitive and quantitative
o High Throughput-compatible
o Coexpressed Active human P450-NADPH Reductase combo included
o Validated with pooled human liver microsomes and specific inhibitors

Applications:

o Rapid assessment of native/recombinant CYP activity in lysates or microsomal fractions prepared from tissues or cells.
o Screening of drugs and novel ligands for interaction with native/recombinant CYPs.
o Development of structure-activity relationship (SAR) models to predict CYP inhibition liability of novel compounds.
o Prediction of adverse drug-drug interaction potential and bioavailability for compounds metabolized by CYPs

BioVision's Drug Metabolism Assay kit portfolio:http://www.biovision.com/drug-metabolism-and-disposition-... and EZCyp™ Active Human Cytochrome P450 product line: http://www.biovision.com/search/results.html?keywords=EZC...